Related Experiment Video

Updated: Jul 15, 2026

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
10:26

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Published on: January 16, 2015

Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in

Jing Tan1, Xiaojing Yang, Li Zhuang

  • 1Molecular Pharmacology, Genome Institute of Singapore, 138672, Singapore.

Genes & Development
|April 18, 2007
PubMed

Insights

The Polycomb-repressive complex 2 (PRC2) inhibitor 3-Deazaneplanocin A (DZNep) effectively triggers cancer cell death by reactivating silenced genes. This chromatin remodeling compound shows promise as a novel cancer therapy.

Area of Science:

  • Epigenetics and Cancer Biology
  • Chromatin Remodeling
  • Pharmacology

Background:

  • Polycomb-repressive complex 2 (PRC2) mediates histone methylation, crucial for aberrant gene silencing in cancer.
  • PRC2 is a potential therapeutic target for various cancers.

Purpose of the Study:

  • To investigate the effects of the PRC2 inhibitor 3-Deazaneplanocin A (DZNep) on cancer cells.
  • To identify genes regulated by PRC2 in breast cancer and their reactivation by DZNep.
  • To elucidate the mechanism of DZNep-induced apoptosis in cancer cells.

Main Methods:

  • Utilized RNA interference (RNAi), genome-wide expression analysis, and chromatin immunoprecipitation (ChIP).
  • Assessed cellular levels of PRC2 components (EZH2, SUZ12, EED) and histone methylation.
  • Investigated gene reactivation and apoptosis induction by DZNep.

Main Results:

  • DZNep induced apoptosis in cancer cells but not normal cells.
  • DZNep depleted PRC2 components and inhibited H3 Lys 27 methylation.
  • Identified and demonstrated reactivation of PRC2-repressed genes, including FBXO32, by DZNep, contributing to apoptosis.

Conclusions:

  • DZNep is a novel chromatin remodeling compound with selective anti-cancer effects.
  • Pharmacologic reversal of PRC2-mediated gene repression by DZNep offers a potential new cancer therapy approach.

More Related Videos

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size reduction of the tissue.